Measurement of copeptin levels in plasma

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.

• Sepsis, severe sepsis, septic shock, lower respiratory tract infections, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases, i.e., chronic heart failure may increase copeptin concentrations.1-3
• Arginine vasopressin (AVP) receptor antagonist therapies and other diseases in which AVP has been shown to play an important pathophysiologic role may also increase copeptin concentration
• Mixed forms of diabetes insipidus (DI) can exist, and both central and peripheral DI may be incomplete, complicating the interpretation of results
• Patients with long-standing psychogenic polydipsia may have copeptin levels suggestive of mild nephrogenic DI.
• While an elevated plasma copeptin concentration in a hyponatremic patient can be suggestive of the syndrome of inappropriate antidiuretic hormone secretion (SIADH), copeptin determination alone is not typically sufficient to distinguish SIADH from other hyponatremic disorders.4,5
• Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedures, may have circulating anti-animal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.

Lavender (EDTA), 4mL

Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting

1. Centrifuge sample within 2 hours of collection.
2. Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp) labelled as EDTA plasma

Transfer vial/tube with cap - 12mL (LabCorp)

Refrigerated (preferred) - 14 days

Frozen - 14 days

Ambient - 14 days

Freeze/thaw cycles - stable x3

• Gross lipemia
• Gross hemolysis
• Gross icterus

The ThermoFisher/BRAHMS KRYPTOR® assay employs Time-Resolved Amplified Cryptate Emission Cryptate Emission (TRACE) technology based on a non-radioactive energy transfer between a donor (europium cryptate) and an acceptor (XL665) in a sandwich immunofluorescent format using two mouse monoclonal antibodies.

0.0–5.9 pmol/L

Reference interval derived from testing of non-water deprived, non-fasting adults.